Literature DB >> 10571192

Association of prostate size with urinary morbidity following mixed conformal neutron and photon irradiation.

J D Forman1, S Keole, S Bolton, S Tekyi-Mensah.   

Abstract

PURPOSE: This study was designed to characterize the relationship between the observed rate of postradiation genitourinary (GU) complications and the prostate gland size. METHODS AND MATERIALS: Two hundred seventy-three patients received conformal neutron and photon irradiation to the prostate seminal vesicles. Data on post-treatment urinary morbidity were collected and examined in relationship to a number of clinical and technical factors.
RESULTS: With a median follow-up of 30 months (range 7-61), the 4-year rate of Grade 2 or higher GU complications was 21%. On univariate analysis, the risk of complications was significantly associated with prostate size and neutron beam arrangement. On multivariate analysis, only the prostate size was significantly associated with the risk of GU morbidity. Patients with a preradiation prostate volume more than 74 cc had a two and a half fold increase in the risk of complications compared to patients with smaller glands.
CONCLUSION: Patients with an enlarged prostate have a significantly higher risk of chronic GU complications. Although these data were obtained for patients receiving combined neutron and photon irradiation, it is likely that these data would also be applicable for those patients receiving photon irradiation as well. These observations may add an additional rationale for the study of preirradiation hormonal treatment.

Entities:  

Mesh:

Year:  1999        PMID: 10571192     DOI: 10.1016/s0360-3016(99)00275-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  1 in total

1.  Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO).

Authors:  Jesper Carl; Dirk Rades; Claudia Doemer; Cornelia Setter; Jürgen Dunst; Niels Henrik Holländer
Journal:  Radiat Oncol       Date:  2019-01-10       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.